- Home
- OIM vs LCTX Comparison
OIM vs LCTX Comparison
Compare OIM & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIM | LCTX |
|---|---|---|
| Founded | 2025 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.3M | 301.7M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OIM | LCTX |
|---|---|---|
| Price | $10.11 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 16.7K | ★ 990.1K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $9.96 | $0.95 |
| 52 Week High | $10.33 | $2.09 |
Technical Indicators
Market Signals| Indicator | OIM | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | N/A |
| Support Level | $10.06 | N/A |
| Resistance Level | $10.33 | N/A |
| Average True Range (ATR) | 0.02 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 38.46 | 0.00 |
Price Performance
Historical ComparisonAbout OIM OneIM Acquisition Corp. Class A Ordinary Shares
OneIM Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.